CN88101370A - 作用于心血管系统的药物组合物及其制备方法 - Google Patents

作用于心血管系统的药物组合物及其制备方法 Download PDF

Info

Publication number: CN88101370A
Authority: CN; China
Prior art keywords: mass; selenium; composition; algae; double bonds
Prior art date: 1987-03-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN88101370A

Other languages

English (en)

Chinese (zh)

Inventor

盖尔格·巴克太

彼得·利特瑞特·那格

拉热丝·盖尔格·那格

盖尔格·布拉克

米克劳丝·哥瑞斯

雅诺斯·派里那克

玛瑞雅·包瑞斯

米克劳丝·法毕安

埃塞比特·巴克

拉斯劳·巴哥那牙

加保·奶米特

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kola Cometkay Hattstartawi Parry Vallard

Original Assignee

Kola Cometkay Hattstartawi Parry Vallard

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-03-18

Filing date

1988-03-18

Publication date

1988-11-09

1988-03-18 Application filed by Kola Cometkay Hattstartawi Parry Vallard filed Critical Kola Cometkay Hattstartawi Parry Vallard

1988-11-09 Publication of CN88101370A publication Critical patent/CN88101370A/zh

Status Pending legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
210000000748 cardiovascular system Anatomy 0.000 title claims abstract description 8
238000002360 preparation method Methods 0.000 title claims description 6
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 36
229910052711 selenium Inorganic materials 0.000 claims abstract description 36
239000011669 selenium Substances 0.000 claims abstract description 36
239000000194 fatty acid Substances 0.000 claims abstract description 10
238000000034 method Methods 0.000 claims abstract description 7
239000003963 antioxidant agent Substances 0.000 claims abstract description 6
239000000969 carrier Substances 0.000 claims abstract description 6
239000000654 additive Substances 0.000 claims abstract description 5
239000000203 mixture Substances 0.000 claims description 33
241000195493 Cryptophyta Species 0.000 claims description 32
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 21
235000014113 dietary fatty acids Nutrition 0.000 claims description 9
229930195729 fatty acid Natural products 0.000 claims description 9
150000004665 fatty acids Chemical class 0.000 claims description 9
235000021323 fish oil Nutrition 0.000 claims description 9
235000021122 unsaturated fatty acids Nutrition 0.000 claims description 8
150000004670 unsaturated fatty acids Chemical class 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
239000013535 sea water Substances 0.000 claims description 2
SBHCLVQMTBWHCD-METXMMQOSA-N (2e,4e,6e,8e,10e)-icosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C(O)=O SBHCLVQMTBWHCD-METXMMQOSA-N 0.000 claims 1
HXWJFEZDFPRLBG-UHFFFAOYSA-N Timnodonic acid Natural products CCCC=CC=CCC=CCC=CCC=CCCCC(O)=O HXWJFEZDFPRLBG-UHFFFAOYSA-N 0.000 claims 1
WXWWHMAUMNQUSF-UHFFFAOYSA-N icosa-7,10,13,16,19-pentaenoic acid Chemical compound OC(=O)CCCCCC=CCC=CCC=CCC=CCC=C WXWWHMAUMNQUSF-UHFFFAOYSA-N 0.000 claims 1
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 32
235000011649 selenium Nutrition 0.000 description 29
229940091258 selenium supplement Drugs 0.000 description 29
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 20
229960005135 eicosapentaenoic acid Drugs 0.000 description 20
235000020673 eicosapentaenoic acid Nutrition 0.000 description 20
235000020669 docosahexaenoic acid Nutrition 0.000 description 18
229940090949 docosahexaenoic acid Drugs 0.000 description 16
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
239000003026 cod liver oil Substances 0.000 description 7
235000012716 cod liver oil Nutrition 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 6
230000008901 benefit Effects 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000000843 powder Substances 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
229930003427 Vitamin E Natural products 0.000 description 4
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
230000009931 harmful effect Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
235000016709 nutrition Nutrition 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
235000020660 omega-3 fatty acid Nutrition 0.000 description 4
239000000126 substance Substances 0.000 description 4
235000019166 vitamin D Nutrition 0.000 description 4
239000011710 vitamin D Substances 0.000 description 4
235000019165 vitamin E Nutrition 0.000 description 4
229940046009 vitamin E Drugs 0.000 description 4
239000011709 vitamin E Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
241000251468 Actinopterygii Species 0.000 description 3
241000195663 Scenedesmus Species 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
235000019688 fish Nutrition 0.000 description 3
230000003902 lesion Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
239000011573 trace mineral Substances 0.000 description 3
235000013619 trace mineral Nutrition 0.000 description 3
238000011282 treatment Methods 0.000 description 3
DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 2
GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000006587 Glutathione peroxidase Human genes 0.000 description 2
108700016172 Glutathione peroxidases Proteins 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
229930003316 Vitamin D Natural products 0.000 description 2
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 2
229940013317 fish oils Drugs 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000007574 infarction Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000011630 iodine Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
230000035764 nutrition Effects 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
229960001471 sodium selenite Drugs 0.000 description 2
239000011781 sodium selenite Substances 0.000 description 2
235000015921 sodium selenite Nutrition 0.000 description 2
208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
235000019155 vitamin A Nutrition 0.000 description 2
239000011719 vitamin A Substances 0.000 description 2
150000003710 vitamin D derivatives Chemical class 0.000 description 2
229940045997 vitamin a Drugs 0.000 description 2
229940046008 vitamin d Drugs 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
206010059150 Cerebrosclerosis Diseases 0.000 description 1
241000195649 Chlorella <Chlorellales> Species 0.000 description 1
241000252203 Clupea harengus Species 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000276438 Gadus morhua Species 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
201000002772 Kwashiorkor Diseases 0.000 description 1
WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
235000008708 Morus alba Nutrition 0.000 description 1
240000000249 Morus alba Species 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
206010033078 Otitis media Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
241001125046 Sardina pilchardus Species 0.000 description 1
241000269821 Scombridae Species 0.000 description 1
206010039921 Selenium deficiency Diseases 0.000 description 1
241000238371 Sepiidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000004061 bleaching Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000001058 brown pigment Substances 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229940107161 cholesterol Drugs 0.000 description 1
235000019516 cod Nutrition 0.000 description 1
239000000306 component Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000034994 death Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
210000003617 erythrocyte membrane Anatomy 0.000 description 1
PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
239000013505 freshwater Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
206010019692 hepatic necrosis Diseases 0.000 description 1
235000019514 herring Nutrition 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
231100000149 liver necrosis Toxicity 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
235000020640 mackerel Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
230000003228 microsomal effect Effects 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028320 muscle necrosis Diseases 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000005445 natural material Substances 0.000 description 1
230000009965 odorless effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
201000001245 periodontitis Diseases 0.000 description 1
238000005502 peroxidation Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000002994 raw material Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
235000019512 sardine Nutrition 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000010686 shark liver oil Substances 0.000 description 1
229940069764 shark liver oil Drugs 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Natural Medicines & Medicinal Plants (AREA)
Biotechnology (AREA)
Cardiology (AREA)
Hematology (AREA)
Alternative & Traditional Medicine (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Inorganic Chemistry (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Botany (AREA)
Medical Informatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CN88101370A 1987-03-18 1988-03-18 作用于心血管系统的药物组合物及其制备方法 Pending CN88101370A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU871173A HU204199B (en)	1987-03-18	1987-03-18	Process for producing pharmaceutical compositions containing unsaturated fatty acids and selenium as active components
HU1173/87		1987-03-18

Publications (1)

Publication Number	Publication Date
CN88101370A true CN88101370A (zh)	1988-11-09

Family

ID=10953170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN88101370A Pending CN88101370A (zh)	1987-03-18	1988-03-18	作用于心血管系统的药物组合物及其制备方法

Country Status (23)

Country	Link
CN (1)	CN88101370A (de)
AT (1)	AT395818B (de)
AU (1)	AU610141B2 (de)
BE (1)	BE1002428A3 (de)
CH (1)	CH675075A5 (de)
DD (1)	DD280904A5 (de)
DE (1)	DE3809225A1 (de)
DK (1)	DK148788A (de)
ES (1)	ES2009569A6 (de)
FI (1)	FI881307A7 (de)
FR (1)	FR2612399B1 (de)
GB (1)	GB2203042B (de)
GR (1)	GR1000447B (de)
HU (1)	HU204199B (de)
IL (1)	IL85776A (de)
IT (1)	IT1216142B (de)
LU (1)	LU87169A1 (de)
NL (1)	NL8800693A (de)
NO (1)	NO881214L (de)
PT (1)	PT87017B (de)
SE (1)	SE8800988L (de)
YU (1)	YU55388A (de)
ZA (1)	ZA881957B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU210122B (en) *	1988-03-23	1995-02-28	Biorex Kutato Fejlesztoe Kft	Process for production of composition against thromboembolytic conditions of circulating system and heart
DE3901048A1 (de) *	1989-01-14	1990-07-19	Chimicasa Gmbh	Antikachectikum
GB9001121D0 (en) *	1990-01-18	1990-03-21	Efamol Holdings	Efa compositions and therapy
GB2363331B (en) *	2000-06-17	2003-02-05	Raymond Clifford Noble	Supplement to enhance fertility
FR2816211B1 (fr) *	2000-11-08	2005-04-01	Brif	Nouvelles compositions dietetiques et ou/cosmetiques pour ameliorer la secheresse des muqueuses
US20040076695A1 (en)	2002-07-08	2004-04-22	Advanced Vision Research	EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
AU2003214316A1 (en) *	2003-01-14	2004-09-06	Francois Bruneau	Photosynthetic micro-organisms enriched with biologically-active molecules, preparation method thereof and uses of same
CN107998227A (zh) *	2016-10-28	2018-05-08	新时代健康产业（集团）有限公司	一种保护心脏的保健品及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4513008A (en) *	1982-07-30	1985-04-23	The Vinoxen Company, Inc.	Virucidal compositions and therapy
CA1239587A (en) *	1983-10-24	1988-07-26	David Rubin	Combined fatty acid composition for lowering blood cholestrol and triglyceride levels

1987
- 1987-03-18 HU HU871173A patent/HU204199B/hu not_active IP Right Cessation
1988
- 1988-03-17 CH CH1007/88A patent/CH675075A5/de not_active IP Right Cessation
- 1988-03-17 IL IL85776A patent/IL85776A/xx unknown
- 1988-03-18 LU LU87169A patent/LU87169A1/fr unknown
- 1988-03-18 GB GB8806530A patent/GB2203042B/en not_active Expired - Fee Related
- 1988-03-18 ZA ZA881957A patent/ZA881957B/xx unknown
- 1988-03-18 BE BE8800307A patent/BE1002428A3/fr not_active IP Right Cessation
- 1988-03-18 GR GR880100170A patent/GR1000447B/el unknown
- 1988-03-18 NL NL8800693A patent/NL8800693A/nl not_active Application Discontinuation
- 1988-03-18 FI FI881307A patent/FI881307A7/fi not_active IP Right Cessation
- 1988-03-18 YU YU00553/88A patent/YU55388A/xx unknown
- 1988-03-18 AT AT0073788A patent/AT395818B/de not_active IP Right Cessation
- 1988-03-18 DE DE3809225A patent/DE3809225A1/de not_active Withdrawn
- 1988-03-18 FR FR888803513A patent/FR2612399B1/fr not_active Expired - Fee Related
- 1988-03-18 DK DK148788A patent/DK148788A/da not_active Application Discontinuation
- 1988-03-18 PT PT87017A patent/PT87017B/pt not_active IP Right Cessation
- 1988-03-18 ES ES8800825A patent/ES2009569A6/es not_active Expired
- 1988-03-18 CN CN88101370A patent/CN88101370A/zh active Pending
- 1988-03-18 SE SE8800988A patent/SE8800988L/xx not_active Application Discontinuation
- 1988-03-18 AU AU13261/88A patent/AU610141B2/en not_active Ceased
- 1988-03-18 IT IT8819838A patent/IT1216142B/it active
- 1988-03-18 NO NO881214A patent/NO881214L/no unknown
- 1988-03-18 DD DD88313814A patent/DD280904A5/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
GR880100170A (en)	1989-01-31
GB2203042A (en)	1988-10-12
IT8819838A0 (it)	1988-03-18
AT395818B (de)	1993-03-25
FR2612399A1 (fr)	1988-09-23
CH675075A5 (de)	1990-08-31
IL85776A (en)	1992-09-06
ES2009569A6 (es)	1989-10-01
DK148788D0 (da)	1988-03-18
GB2203042B (en)	1990-10-03
SE8800988L (sv)	1988-09-19
ATA73788A (de)	1992-08-15
FI881307L (fi)	1988-09-19
ZA881957B (en)	1989-01-25
AU610141B2 (en)	1991-05-16
HU204199B (en)	1991-12-30
DE3809225A1 (de)	1988-11-03
NO881214D0 (no)	1988-03-18
AU1326188A (en)	1988-09-22
BE1002428A3 (fr)	1991-02-05
DK148788A (da)	1988-09-19
GB8806530D0 (en)	1988-04-20
JPS6427A (en)	1989-01-05
FI881307A7 (fi)	1988-09-19
YU55388A (en)	1989-10-31
IT1216142B (it)	1990-02-22
FI881307A0 (fi)	1988-03-18
PT87017B (pt)	1992-06-30
GR1000447B (el)	1992-07-30
LU87169A1 (fr)	1989-10-26
PT87017A (pt)	1988-04-01
NO881214L (no)	1988-09-19
DD280904A5 (de)	1990-07-25
HUT52388A (en)	1990-07-28
NL8800693A (nl)	1988-10-17
SE8800988D0 (sv)	1988-03-18
IL85776A0 (en)	1988-09-30
FR2612399B1 (fr)	1991-03-29

Legal Events

Date	Code	Title
1988-11-09	C06	Publication
1988-11-09	PB01	Publication
1990-07-25	C10	Entry into substantive examination
1990-07-25	SE01	Entry into force of request for substantive examination
1993-07-21	C01	Deemed withdrawal of patent application (patent law 1993)
1993-07-21	WD01	Invention patent application deemed withdrawn after publication

Publication	Publication Date	Title
ES2576578T3 (es)	2016-07-08	Composición de ácidos grasos n-3 que presentan una concentración elevada de EPA y/o DHA y que contiene ácidos grasos n-6
AU2014202880B2 (en)	2017-08-31	Production and purification of esters of polyunsaturated fatty acids
RU2276975C2 (ru)	2006-05-27	Терапевтические комбинации жирных кислот
CA1319607C (en)	1993-06-29	Antithrombotic pharmaceutical preparation and process for preparing same
HU200686B (en)	1990-08-28	Process for producing pharmaceutical compositions comprising epa and/or dha, suitable for treating or preventing rheumatic arthritis
KR20040004652A (ko)	2004-01-13	조효소 ｑ 및 에이코사펜타에노산（ｅｐａ）
JP2004506657A (ja)	2004-03-04	天然および合成ｈｃａのバイオアベイラブルな組成物
CN1160990A (zh)	1997-10-01	配合有ω6系·ω3系不饱和脂肪酸的平衡调节剂的食品组合物
CN88101370A (zh)	1988-11-09	作用于心血管系统的药物组合物及其制备方法
US7943186B2 (en)	2011-05-17	Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight
JPH0761954B2 (ja)	1995-07-05	コレステロール低下または上昇抑制剤
JPH012551A (ja)	1989-01-06	食餌性組成物およびその製造方法
FR2612373A1 (fr)	1988-09-23	Compositions dietetiques et procede pour leur preparation
KR20050029582A (ko)	2005-03-28	알지닌 공액리놀레인산 복합체를 포함하는 항산화 조성물
CH651294A5 (fr)	1985-09-13	Acides amino-2-halogenobenzoyl-3-methylphenylacetiques et leurs esters et sels utiles comme medicaments anti-inflammatoires et analgesiques.
FR2612396A1 (fr)	1988-09-23	Compositions cosmetiques regenerant la peau et leur procede de preparation
JPH0127A (ja)	1989-01-05	心臓および心臓血管系に作用する薬剤並びにその製造方法
EP1433500B1 (de)	2006-07-19	Die Blut-Fluidität verbessernde Lebensmittel
CN112220048A (zh)	2021-01-15	能够同时促进肌肉和骨骼健康的组合物及其制备方法
JP2003321360A (ja)	2003-11-11	植物の果実から抽出した果実油、その抽出方法、医薬組成物およびその用途
JPH06199693A (ja)	1994-07-19	虚血性疾患改善治療剤
CN1313091C (zh)	2007-05-02	维生素c组合物
KR101481040B1 (ko)	2015-01-14	[10]-진저다이온 또는 1-데하이드로-[10]-진저다이온을 포함하는 항 염증용 조성물
JP3441357B2 (ja)	2003-09-02	脳卒中抑制剤
BE723288A (de)	1969-04-01